This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Mittal, G Articles by Joshi, V R Search for Related Content PubMed PubMed Citation Articles by Mittal, G Articles by Joshi, V R Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB CYCLOPHOSPHAMIDE Medline Plus Health Information Lupus Social Bookmarking                         What's this?

‘Sustained remission’ in a case of SLE following megadose cyclophosphamide

Rheumatology Division, P. D. Hinduja National Hospital & Research Centre, Veer Savarkar Marg, Mahim, Mumbai 400 016, India: Rheumatology P.D. Hinduja National Hospital, Veer Savarkar Marg, Mahim, Mambai 400 016, India.

C Balakrishna

Rheumatology Division, P. D. Hinduja National Hospital & Research Centre, Veer Savarkar Marg, Mahim, Mumbai 400 016, India

G Mangat

Rheumatology Division, P. D. Hinduja National Hospital & Research Centre, Veer Savarkar Marg, Mahim, Mumbai 400 016, India

V R Joshi

Cytotoxic therapy, especially with cyclophosphamide in the dose 8–20 mg/kg used as intermittent pulses, has been shown to improve both patient and renal survival in systematic lupus erythematosus (SLE), but to date there is no cure for the disease. Owing to the paucity of recognisable clones, the rationale and goal of cytotoxic immunosuppressive therapy in the treatment of immune-mediated diseases as against malignancies is to suppress the aberrant infiammation and immune-mediated reactions responsible for tissue damage, without dangerously suppressing the normal host defence mechanism(s). We report the case of a patient suffering from SLE with nephritis who has remained in sustained remission over the past 8 years without any maintenance therapy following an accidental administration of a single dose of 5000 mg of intravenous cyclophosphamide (44.2 mg/kg body weight). The patient recovered fully from pancytopenia following the injection. Presently, she is asymptomatic and working gainfully. Her laboratory parameters including blood counts, urine analysis, FANA and anti-dsDNA have reverted to normal. Cyclophosphamide in the dose of 30–160 mg/kg has been safely and effectively used in various neoplastic conditions with the aim of destroying every possible tumour cell. The experience of the present case suggests that such an approach may be applicable to SLE.

Key Words: SLE • nephritis • cyclophosphamide • remission

Lupus, Vol. 8, No. 1, 77-80 (1999)
DOI: 10.1191/096120399678847326


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?